Infliximab in a patient with refractory mucosal aphthosis [7]

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 1, 2008, Pages 109-110

  Jacobi, Arnd ^a   Debus, D ^b   Schuler, G ^c   Hertl, M ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b Nuremberg Hospital   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DAPSONE; INFLIXIMAB; ISOTRETINOIN; POVIDONE IODINE; PREDNISONE; RETINOID DERIVATIVE;

ADULT; APHTHOUS STOMATITIS; CASE REPORT; CROHN DISEASE; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LETTER; LIP; PALATE; PRIORITY JOURNAL; REMISSION; SKIN DEFECT; TONGUE; TREATMENT DURATION; VAGINA MUCOSA;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; MUCOUS MEMBRANE; STOMATITIS, APHTHOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37749009589     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02270.x     Document Type: Letter

References (6)

1. Jacobi A, Mahler V, Schuler G, Hertl M. Treatment of inflammatory dermatoses by tumor necrosis factor antagonists. J Eur Acad Dermatol Venereol 2006; 20: 1171-1187.
2. Sands BE, Anderson FH, Bernstein CN et.al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885.
3. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001; 7: 38-42.
4. Ferkolj I, Ihan A, Markovic S, Veceric Z, Pohar M. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease. J Gastrointestin Liver Dis 2006; 15: 231-235.
5. Meijer MJ, Mieremet-Ooms MA, van Duijn W et.al. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 200-210.
6. Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006; 9: 221-233.